(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Humira has been one of the world's top selling drugs for more than two decades. But thanks to some new copycats — including one that is being sold at entrepreneur Mark Cuban's online pharmacy — its ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

(Reuters) -Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said ...

This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...

As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs... Blockbuster drug Humira finally faces lower-cost ...

The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' (NOVN.S), opens new tab Sandoz generics division, as well as German drugmaker Boehringer Ingelheim's ...

Jan 3 (Reuters) - CVS Health CVS.N said on Wednesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April ...